Ed Kaye, Stoke Therapeutics CEO

Stoke Ther­a­peu­tics un­veils more da­ta on stud­ies of Dravet drug, hint­ing at im­prove­ments to cog­ni­tion and be­hav­ior

Stoke Ther­a­peu­tics pre­sent­ed more da­ta on its in­ves­ti­ga­tion­al Dravet syn­drome treat­ment on Tues­day morn­ing, say­ing it helped re­duce seizures and im­prove cer­tain cog­ni­tive and be­hav­ioral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.